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The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib is
approved by the Food and Drug Administration for its use
as ﬁrst-line treatment in chronic lymphocytic leukemia
(CLL). Despite its efﬁcacy, patients treated with ibrutinib
rarely achieve complete responses and usually remain
under treatment until progression. Considering the
inherent high susceptibility of CLL patients to infections,
a better understanding of ibrutinib effects on the immune
system might help to estimate the risk of infectious
complications on treated patients. Besides its effects on
leukemic B cells, ibrutinib also affects functions on T cells,
natural killer cells, and macrophages1–3. Macrophages are
central players of the innate immune response against
fungi, extracellular bacteria, and in particular against the
intracellular bacteria Mycobacterium tuberculosis (Mtb).
The World Health Organization (WHO) estimates that
one-third of the world’s population is infected with Mtb,
the causing agent of tuberculosis, a severe infection that
kills near 1.3 million people per year and the leading cause
of death from a single infectious agent (Global TB report,
WHO, 2017). Notably, the incidence rate of tuberculosis
is highly variable among different countries. In South
American countries, such as Argentina and Brazil, where
ibrutinib is being introduced, the rates of tuberculosis
incidence are up to 14 times higher than in USA and
other developed countries. Given the relevance of mac-
rophages in Mtb immune response, we here evaluated the
in vitro effects of ibrutinib on this cell compartment.
Additionally, we studied its effects on γδ T cells, another
innate immune component reported to be involved in
Mtb response4. Strikingly, we found that ibrutinib affects
macrophage's phenotype and the response of both mac-
rophages and γδ T cells to Mtb.
Macrophages were differentiated from human mono-
cytes with macrophage colony-stimulating factor (M-
CSF), then pre-treated with ibrutinib for 30 min, and
afterward exposed to irradiated Mtb for 24 h. We found
that clinically relevant doses of ibrutinib (0.03–0.3 µM)
signiﬁcantly reduced the release of tumor necrosis factor
(TNF)-α (Fig. 1a and Supplementary Fig. 1a), while
interleukin (IL)-10 and IL-8 secretion was only affected at
3 µM, which is a concentration higher than the one
reported in the plasma of treated patients (Fig. 1b, c).
Importantly, macrophage viability was not affected by
ibrutinib (Supplementary Fig. 1b). Inhibition of TNF-α
secretion was associated with a diminished phosphoryla-
tion of the p65 subunit of the transcription factor nuclear
factor (NF)-kB (Fig. 1d), a key regulator of cytokine pro-
duction in macrophages. Given the relevance of Toll-like
receptor (TLR) 2 and TLR4 in Mtb recognition by mac-
rophages, we evaluated the effect of ibrutinib on TNF-α
secretion in response to lipopolysaccharide (LPS), a TLR4
ligand, and Pam3CSK4, a TLR2 ligand. Results in Fig. 1e
show that ibrutinib impaired TNF-α secretion induced by
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Fig. 1 Ibrutinib impairs macrophage-mediated response against Mycobacterium tuberculosis. Macrophages were obtained by culturing
monocytes from healthy donors (HD) or CLL patients for 5 days in RPMI 10% FCS in the presence of M-CSF (50 ng/ml). a–c HD-macrophages were
stimulated with irradiated Mtb (MOI equivalent to 2) in the presence or absence of ibrutinib (Ibru) and after 24 h TNF-α, IL-8, and IL-10 secretion was
measured by ELISA in culture supernatants. Bars represent mean ± SEM of cytokine concentration in control (ct.) cultures (white bars) or Mtb-
stimulated cultures (gray bars). n= 10, *p < 0.05, Kruskal–Wallis test, followed by Dunn’s multiple comparisons test. d Phosphorylation of p65 (p-p65)
was evaluated by western blot in HD macrophages after 15 min of stimulation with Mtb in the presence or absence of ibrutinib. Bands on the
immunoblots were quantiﬁed using the ImageJ software (NIH Image). Results are shown as the mean ± SEM of the ratio p-p65/β-actin in arbitrary
units (A.U.). n= 6, *p < 0.05, Friedman test, followed by Dunn’s multiple comparisons test. e HD macrophages were stimulated with LPS (100 ng/ml)
or Pam3CSK4 (100 ng/ml) in the presence or absence of ibrutinib for 24 h and TNF-α production was measured in culture supernatants by ELISA. n=
10, *p < 0.05, Kruskal–Wallis test, followed by Dunn’s multiple comparisons test. f CLL macrophages were stimulated with irradiated Mtb (MOI
equivalent to 2), LPS (100 ng/ml), or Pam3CSK4 (100 ng/ml) in the presence or absence of ibrutinib for 24 h and TNF-α production was measured by
ELISA in culture supernatants. n= 7, *p < 0.05, Kruskal–Wallis test, followed by Dunn’s multiple comparisons test
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these ligands. Of note, the inhibition in response to TLR2,
but not to TLR4, stimulation was observed even at low
concentrations of ibrutinib (30 nM) (Supplementary Fig.
1c, d), suggesting a differential involvement of BTK, or
other ibrutinib targets, in TLR2 and TLR4 signaling
pathways. Inhibition of TNF-α secretion in response to
Mtb, Pam3CSK4, and LPS was also observed in ibrutinib-
treated monocyte-derived macrophages from CLL
patients (Fig. 1f). Clinical characteristics of CLL patients
included in this study are presented in Supplementary
Table 1.
Then, given that macrophages with different polariza-
tion proﬁles have different abilities to promote an efﬁcient
immune response against Mtb, the M1 pro-inﬂammatory
proﬁle being more effective than the M2 anti-
inﬂammatory proﬁle5, we aimed to evaluate the effect of
ibrutinib on macrophage polarization in interferon (IFN)-
γ-induced M1, IL4-induced M2, and IL-10-induced M2
proﬁles. M1 and M2 polarization was conﬁrmed by ana-
lyzing the expression of CD16, CD14, CD163, CD206,
CD86, and HLA-DR by ﬂow cytometry (Supplementary
Fig. 2). We found that ibrutinib impaired M1 polarization
as shown by the upregulation of M2-associated markers
CD16, CD14, CD163, and CD206 and by downregulation
of the M1-associated markers CD86 and HLA-DR (Fig.
2a, b). The expression of these markers was not modiﬁed
by ibrutinib on IL-4- and IL-10-induced M2 macrophages
(Supplementary Fig. 3). These results are in line with
those recently published by Fiocari et al. showing that
ibrutinib promotes an M2 phenotype in nurse-like cells
from CLL patients2. Impairment in M1 polarization,
induced upon ibrutinib exposure, was not associated with
a decrease in signal transducer and activator of tran-
scription factor (STAT) 1 phosphorylation (Supplemen-
tary Fig. 4). Interestingly, we found that ibrutinib
enhanced macrophage three-dimensional migration in
Matrigel (Fig. 2c), a feature of macrophage with an M2
proﬁle6. We also found that M1 macrophages polarized in
the presence of ibrutinib showed a decreased secretion of
TNF-α and an increased secretion of IL-10 compared to
control M1 macrophages, resembling the cytokine proﬁle
associated with M2 macrophages (Fig. 2d). M1 and M2
macrophages also differ in their glucose metabolic path-
ways. During M1 polarization, macrophages activate the
aerobic glycolytic pathway, increasing glucose uptake and
lactate production, while M2 macrophages preferentially
use the oxidative metabolism to obtain energy. Impor-
tantly, this switch towards aerobic glycolysis seems to be
necessary for an effective differentiation into the M1
proﬁle7. We found that ibrutinib treatment of M1 mac-
rophages reduced both glucose consumption and lactate
production (Fig. 2e). The impairment in M1 polarization,
and the reduction in glucose consumption and lactate
production induced by ibrutinib were also conﬁrmed in
macrophages from CLL patients (Supplementary Fig. 5).
We also evaluated whether ibrutinib affects the func-
tionality of polarized macrophages and found that ibru-
tinib decreased TNF-α production in response to Mtb and
increased migration in matrigel in M1 macrophages
(Supplementary Fig. 6). Taken together, these results
showed that ibrutinib affects M1 polarization of macro-
phage and their function, which could have detrimental
consequences on the immune response to Mtb in patients
treated with ibrutinib.
Then, since treatment of macrophages with ibrutinib
during M1 polarization increased CD206 expression (Fig.
2a), a receptor involved in Mtb phagocytosis, we evaluated
whether macrophage phagocytosis and/or the intracel-
lular growth of Mtb was affected in this situation. As
shown in Fig. 2f, M1 macrophages polarized in the pre-
sence of ibrutinib showed a slight increase in Mtb uptake,
while the intracellular growth of the bacteria was not
modiﬁed (Supplementary Fig. 7). On the other hand,
when we compared the effect of ibrutinib on the intra-
cellular growth of already infected M1 macrophages, we
found that ibrutinib impaired their killing capacity as
shown by the increase in the bacillary load (Fig. 2g, h).
T cells bearing the γδ T cell receptor also participate in
the innate host defense against Mtb. γδ T cells are found
in Mtb-induced lesions in humans, they release IFN-γ in
response to Mtb, a cytokine associated with protective
immunity, and are cytotoxic against Mtb-infected mac-
rophages resulting in killing of intracellular bacilli4.
Therefore, we evaluated the effect of ibrutinib on human
γδ T cells stimulated with Mtb and found a signiﬁcant
decrease in the expression of the activation marker CD69
and in the secretion of IFN-γ (Fig. 2i, j), suggesting that γδ
T cell response to Mtb might also be compromised in
ibrutinib-treated patients.
Results presented here show that ibrutinib affects
macrophages and γδ T cells, which are important players
in an effective immune response to Mtb. In particular, we
observed that ibrutinib, used at doses found in the plasma
of treated patients (0.03–0.3 µM), impairs immune
mechanisms that contribute to the control of Mtb infec-
tion such as TNF-α secretion by macrophages, M1
polarization, Mtb intracellular growth in M1 macro-
phages, and IFN-γ secretion by γδ T cells. Importantly,
the ability of the host to limit Mtb at the site of infection
depends on the formation and maintenance of an effective
granuloma structure. In this context, TNF-α production
by activated macrophages plays a key role in Mtb control
by promoting granuloma formation. In fact, patients
treated with TNF-α-blocking agents have an increased
risk of tuberculosis and the assessment of latent infection
is recommended before starting such treatment. Our
results showing that ibrutinib signiﬁcantly decrease TNF-
α secretion in response to Mtb suggests that this
Colado et al. Blood Cancer Journal           (2018) 8:100 Page 3 of 6
Blood Cancer Journal
Fig. 2 (See legend on next page.)
Colado et al. Blood Cancer Journal           (2018) 8:100 Page 4 of 6
Blood Cancer Journal
mechanism might be compromised in ibrutinib-treated
patients.
Although ibrutinib treatment in CLL is associated with
lower rates of infections compared to the standard che-
moimmunotherapy (Fludarabine, Cyclophosphamide,
Rituximab), major infections, particularly those of the
respiratory tract, are still signiﬁcant, reported in about
one-third of ibrutinib-treated patients8–10. The risk of
infections appears to be highest during the ﬁrst 6 months
of treatment, and a subsequent improvement in patient's
cellular immunity has been suggested by the observation
that ibrutinib favors a Th1 polarization1 and an increase
in the T cell repertory11. Also, recovery from a refractory
state of monocytes and T cells, by the downregulation in
programmed cell death protein 1/programmed cell death
ligand 1 expression, was suggested in a study with a small
cohort (n= 4) of ibrutinib-treated patients12. Never-
theless, over the past years, opportunistic infections dur-
ing ibrutinib treatment such as invasive pulmonary
aspergillosis, disseminated fusarium infection, and dis-
seminated cryptococcal disease have been reported13, and
remarkably in 2015, a case of a CLL patient who devel-
oped miliary tuberculosis 1 month after initiation of
ibrutinib treatment was reported14. In most of those cases,
patients did not present neutropenia and showed normal
levels of T cells suggesting that other/s component/s of
the immune system might be affected in ibrutinib-treated
patients. Moreover, an association between ibrutinib
treatment and an increased susceptibility to Pneumocystis
jirovecii pneumonia (PCP) in CLL was suggested by Ahn
et al. who showed a 5% of incidence of PCP in a cohort of
96 patients treated with ibrutinib as a single agent15. In
this report, patients who developed PCP did not have a
low CD4+ T cell count, which is considered the primary
risk factor for PCP. Interestingly, alveolar macrophages,
TLR2 signaling, and TNF-α secretion are involved in an
effective immune response against P. jirovecii. Given that
TLR2 is a receptor also involved in the recognition of
motifs present in several fungi, our ﬁnding that ibrutinib
impairs macrophages’ response through TLR2 might
explain, at least in part, the increased susceptibility of
ibrutinib-treated patients to PCP and also the presence of
other opportunistic fungal infections.
Although further studies are needed to conﬁrm the
relevance of our observations in vivo and their impact in
clinical practice, we consider that these results represent a
warning especially in countries with a high incidence of
tuberculosis.
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Fig. 2 Ibrutinib impairs M1 polarization and affects macrophage and γδ T cell response to Mycobacterium tuberculosis. To obtain the M1
proﬁle, monocytes from HD were cultured with GM-CSF (50 ng/ml) for 7 days and IFN-γ (10 ng/ml) was added for the last 2 days of culture. Ibrutinib
(0.3 µM) was added to the culture 30 min before adding IFN-γ. a At day 7, macrophages were detached and stained with anti-CD14 PerCP/Cy5.5, anti-
CD16 FITC, anti-CD86 PerCP/Cy5.5, anti-CD206 FITC, anti-CD163 PE, or anti-HLA-DR FITC and analyzed by using a FACScan ﬂow cytometer (BD
Immunocytometry Systems, San Jose, CA, USA). The results are shown as the mean ﬂuorescence intensity (MFI) normalized to the MFI of the isotype
control, n= 10. b Histograms of a representative experiment are shown. c M1 macrophages differentiated in the presence or absence of ibrutinib
(0.3 µM) as described above were seeded on top of a thick layer of Matrigel in the upper Transwell chamber. The lower chamber was ﬁlled with
medium with CCL5. Migration was quantiﬁed after 3 days. Results are shown as the percentage of migrated macrophages and representative images
are shown in the right panel. Representatives images from the top and inside of matrigel are shown. d M1 macrophages were obtained as described
above. M2 macrophages were obtained by culturing monocytes from healthy donors with M-CSF (50 ng/ml) for 7 days and either IL-4 (20 ng/ml) or
IL-10 (10 ng/ml) were added during the last 2 days of culture. Ibru-M1 macrophages were treated with ibrutinib during the last 2 days of culture. At
day 7, the medium was removed and fresh medium without cytokine was added. Then TNF-α and IL-10 was evaluated after 24 h of culture by ELISA.
Bars show mean ± SEM. e M1 macrophages differentiated in the presence or absence of ibrutinib (0.3 µM) as described above. At day 7, glucose and
lactate concentration in the supernatant was evaluated by using commercial kits. Glucose consumption was calculated as the percentage of glucose
in the culture at day 7 relative to the initial glucose concentration in the medium. f M1 macrophages were differentiated in the presence or absence
of ibrutinib as described before and stimulated with irradiated Mtb-FITC (MOI equivalent to 5) for 2 h, then cells were trypsinized and the percentage
of FITC+ macrophages was analyzed by ﬂow cytometry. Results are shown as the percentage of FITC+ macrophages, n= 10. g, h Monocytes from
healthy donors were differentiated into M1 macrophages and were infected with the red ﬂuorescent protein (RFP) expressing M. tuberculosis strain at
an MOI of 5 during 2 h at 37 °C. Thereafter, ibrutinib at 0.3 µM or vehicle was added. After 48 h, the glass coverslips were ﬁxed with PFA 4% and
stained with BODIPY 493/503 (Life Technologies). Finally, slides were mounted and visualized with a FluoView FV1000 confocal microscope (Olympus,
Tokyo, Japan) equipped with a Plapon ×60/NA1.42 objective and then analyzed with the software ImageJ-Fiji. g Quantiﬁcation of the occupied area
with RFP-M. tuberculosis (expressed as Raw Integrated Density) per cell in z-stacks from confocal laser scanning microscopic images. Individual cells
were deﬁned by BODIPY-stained cellular membranes that allow us to deﬁne the regions of interest for quantiﬁcation. In all, 80–100 cells of random
ﬁelds per condition were analyzed. h Representative microphotographs are shown. i, j Puriﬁed γδ T cells were stimulated with irradiated Mtb (MOI
equivalent to 5) in the presence or absence of ibrutinib. After 24 h, CD69 expression and IFN-γ production were evaluated by ﬂow cytometry and
ELISA, respectively. i Results are shown as the percentage of γδ T cells expressing CD69. j IFN-γ concentration in the culture supernatant evaluated by
ELISA. *p < 0.05, Wilcoxon matched-pairs signed rank test. #p < 0.05, Kruskal–Wallis test, followed by Dunn’s multiple comparisons test
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